1. To be included in the low risk group in the ECOG DCIS trial a patient could have all of the following except?
   A) Grade 2 Disease
   B) 2.9 cm lesion
   C) ER positive disease
   D) 3mm margin
   E) Non-palpable lesion

2. Patients enrolled in the UK Tamoxifen trial who did not get radiotherapy and did not get tamoxifen had a 10% ipsilateral recurrence rate of DCIS. What was the recurrence rate for patients that were randomized to tamoxifen only?
   A) 10%
   B) 8%
   C) 6%
   D) 4%
   E) 2%

3. What percentage of women discontinued treatment (tamoxifen or placebo) in the NSABP B-24 trial?
   A) 61%
   B) 51%
   C) 41%
   D) 31%
   E) 21%

4. Which of the following risk factors is not included in the USC/Van Nuys prognostic index (USC/VNPI)?
   A) Tumor size
   B) Margin width
   C) Age
   D) Histologic classification
   E) Hormone receptor status

5. NSABP B-43 is a trial examining the role of trastuzumab in the treatment of women with Her2neu+ DCIS. Approximately what percentage women enrolled on the trial were Her2neu+?
   A) 25%
   B) 35%
   C) 45%
   D) 55%
   E) 65%